Augmented washed microbiota transplantation for chronic allograft fibrosis in renal transplantation
Authors
Affiliations
Abstract
Background: Current microbiome-based therapies, such as probiotics and fecal microbiota transplantation (FMT), face limitations in efficacy for chronic renal allograft dysfunction (CAD). Washed microbiota transplantation (WMT), an advanced FMT method, shows promise but may benefit from augmentation with disease-specific beneficial microbes. We introduce the novel concept of Holdemanella biformis-augmented WMT (Hb-auWMT), combining WMT with a targeted microbe to enhance CAD therapeutic outcomes.
Methods: We conducted a prospective cohort study on renal transplant recipients with CAD (biopsy showing interstitial fibrosis/tubular atrophy), comparing WMT plus routine therapies to routine therapies alone. Metagenomics analyzed fecal samples from donors, stable and CAD patients to identify key bacteria. CAD mouse models tested Hb-auWMT versus WMT. Multiomics (metagenomics, spatial metabolomics, scRNA-Seq) and functional assays (histopathology, flow cytometry and conditional knockout mice) elucidated mechanisms.
Results: In the chronic allograft fibrosis cohort (n=51 matched pairs), WMT achieved a 64.7% clinical response rate at 12 weeks (vs. 27.5% in controls, p<0.001), improving graft function, reducing fibrosis, and alleviating symptoms like progressive proteinuria. Metagenomics identified Holdemanella biformis as enriched in responders and donors but depleted in CAD patients. In fibrosis mice, Hb-auWMT outperformed WMT, enhancing graft survival (80% vs. 60%), reducing Banff IFTA scores, and improving renal histology (decreased interstitial fibrosis and tubular atrophy). Mechanisms included elevated short-chain fatty acids (butyrate/valerate), which reduced the migration of Cx3cr1+ monocytes from the intestine to the kidney by downregulating CX3CL1 release from injured tubules, thereby preventing downstream STAT3 signaling leading to TGF-β secretion, resulting in anti-fibrotic and anti-EMT effects, maintained epithelial barrier integrity.
Conclusions: WMT is superior to routine therapies for chronic allograft fibrosis. Hb-auWMT further enhances efficacy via SCFA-Cx3cr1-STAT3 signaling, addressing limitations of probiotics and standard FMT. This validates the microbiota transplantation augmentation technology, offering a paradigm for microbiome-based therapies in kidney transplantation.